DCC and colorectal cancer: There are at least three means to achieve this survival advantage: loss of netrin-1 receptors expression, as extensively described in human colorectal cancer for DCC or/and UNC5H (Bernet et al, 2007; Fearon et al, 1990; Shin et al, 2007; Thiebault et al, 2003); loss of downstream death signalling induced by DCC or UNC5H; or gain of autocrine or paracrine expression of the ligand.